![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Emmaus Life Sciences has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-glutamine (PGLG) oral powder for use in the treatment of diverticulosis.
Lead Product(s): L-Glutamine
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Emmaus Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 16, 2020